GlassScriptPhysician profile
Dawn Ellen Topper
NPI 1053868703
$1,916.31
in general payments reported to CMS, 2019-2025
19 companies · $822 in 2025
The $822 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40.05 · 2022: $94.64 · 2023: $349 · 2024: $610 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,781.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $374.43 | 2022-2025 | Unithroid |
| Novo Nordisk INC | $266.58 | 2022-2025 | Ozempic, Rybelsus |
| Corcept Therapeutics | $245.32 | 2023-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $169.66 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $143.78 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Radius Health, INC. | $134.70 | 2023-2025 | |
| Recordati_rare_diseases_inc. | $93.38 | 2023-2025 | Isturisa, Signifor Lar |
| Lilly USA, LLC | $74.74 | 2022-2024 | Zepbound, Jardiance, Mounjaro |
| Insulet Corporation | $72.91 | 2024-2025 | Omnipod |
| Madrigal Pharmaceuticals | $71.14 | 2025 | Rezdiffra |
| Ibsa Pharma INC. | $65.18 | 2022-2025 | Licart, Flector, Tirosint |
| Amgen INC. | $54.17 | 2025 | Evenity |
| Tandem Diabetes Care, INC. | $44.67 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Currax Pharmaceuticals LLC | $26.02 | 2021 | |
| Sequel Med Tech, LLC | $23.42 | 2025 | Twiist |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $15.64 | 2025 | Jatenzo |
| Kowa Pharmaceuticals America, INC. | $14.03 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $13.72 | 2024 | |
| Pfizer INC. | $12.82 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Topper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.